| 0.3223 -0.002 (-0.65%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.41 | 1-year : | 0.46 |
| Resists | First : | 0.35 | Second : | 0.39 |
| Pivot price | 0.31  |
|||
| Supports | First : | 0.28 | Second : | 0.24 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.31 |
| MA(100) : | 0.63 |
MA(250) : | 1.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37 |
D(3) : | 30.9 |
| RSI | RSI(14): 43.2 |
|||
| 52-week | High : | 2.88 | Low : | 0.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SNTI ] has closed below upper band by 39.4%. Bollinger Bands are 81.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.33 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.32 - 0.32 | 0.32 - 0.33 |
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Thu, 01 Oct 2026
What Does Today’s Signal Mean for Senti Biosciences (NASDAQ:SNTI)? - Kalkine Media
Fri, 25 Sep 2026
Senti Biosciences Holdings, Inc. SEC Filing (Sep 25, 2026) - stocktitan.net
Mon, 14 Sep 2026
Celadon affiliate commits $2.5M to Senti Biosciences after merger - Dealroom
Thu, 13 Aug 2026
Senti Biosciences (SNTI) Gains 2.35% as Shares Hold Above Key Support at $0.36 - Insider Sentiment - careplusvn.com
Wed, 15 Jul 2026
Senti Biosciences Spins Off Gene-Circuit Pipeline - AllSci
Wed, 15 Jul 2026
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 1.228e+007 (%) |
| Held by Institutions | 47.9 (%) |
| Shares Short | 605 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.017e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -79 % |
| Return on Assets (ttm) | 370.5 % |
| Return on Equity (ttm) | -65.6 % |
| Qtrly Rev. Growth | 55000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -220.03 |
| EBITDA (p.s.) | -1.475e+007 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -6.22 |
| Dividend | 0 |
| Forward Dividend | 519650 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|